RESEARCH ARTICLE

Feline calicivirus- and murine norovirus-induced COX-2/PGE_2 signaling pathway has proviral effects

Mia Madel Alfajaro, Eun-Hyo Cho, Jun-Gyu Park, Ji-Yun Kim, Mahmoud Soliman, Yeong-Bin Baek, Mun-II Kang, Sang-Ik Park*, Kyoung-Oh Cho*

Laboratory of Veterinary Pathology, College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea

* sipark@chonnam.ac.kr (SIP); choko@chonnam.ac.kr(KOC)

Abstract

Cyclooxygenases (COXs)/prostaglandin E_2 (PGE_2) signaling pathways are known to modulate a variety of homeostatic processes and are involved in various pathophysiological conditions. COXs/PGE_2 signaling pathways have also been demonstrated to have proviral or antiviral effects, which appeared different even in the same virus family. A porcine sapovirus Cowden strain, a member of genus Sapovirus within the Caliciviridae family, induces strong COX-2/PGE_2 but transient COX-1/PGE_2 signaling to enhance virus replication. However, whether infections of other viruses in the different genera activate COXs/PGE_2 signaling, and thus affect the replication of viruses, remains unknown. In the present study, infections of cells with the feline calicivirus (FCV) F9 strain in the genus Vesivirus and murine norovirus (MNV) CW-1 strain in the genus Norovirus only activated the COX-2/PGE_2 signaling in a time-dependent manner. Treatment with pharmacological inhibitors or transfection of small interfering RNAs (siRNAs) against COX-2 enzyme significantly reduced the production of PGE_2 as well as FCV and MNV replications. The inhibitory effects of these pharmacological inhibitors against COX-2 enzyme on the replication of both viruses were restored by the addition of PGE_2. Silencing of COX-1 via siRNAs and inhibition of COX-1 via an inhibitor also decrease the production of PGE_2 and replication of both viruses, which can be attributed to the inhibition COX-1/PGE_2 signaling pathway. These data indicate that the COX-2/PGE_2 signaling pathway has proviral effects for the replication of FCV and MNV, and pharmacological inhibitors against these enzymes serve as potential therapeutic candidates for treating FCV and MNV infections.

Introduction

The Caliciviridae family is composed of small, non-enveloped, icosahedral viruses that possess a single-stranded, positive-sense RNA genome of 7–8 kb in size [1]. This family is comprised of five established genera, Lagovirus, Nebovirus, Norovirus, Sapovirus, and Vesivirus [2], with six additional unclassified new genera tentatively named Recovirus [3], Bavovirus [4, 5] Nacovirus [5–7], Salovirus [8], Sanovirus [9], and Valovirus [10]. The members in this family are
important pathogens in both medical and veterinary fields [1]. For example, feline calicivirus (FCV) belonging to the genus *Vesivirus* causes acute, self-lining oral and upper respiratory tract disease in cats [11]. Moreover, virulent, systemic FCV mutant strains causing severe systemic diseases with edematous and ulcerative skin lesions, jaundice, and a high mortality of up to 67% have recently been found in the US and EU [12–14]. Porcine sapovirus (PSaV), and bovine norovirus and nebovirus cause widespread acute gastroenteritis in piglets and calves, respectively [15–17]. In the medical field, human norovirus and human sapovirus, especially the former, is the leading cause of gastroenteritis in humans, accounting for ~200,000 deaths per annum in children <5 [18–19].

FCV vaccines are available for cats [20]; however, there is a limit on its efficacy because of low or no preventive effect against FCVs with different antigenicity and short-lived immunity [13, 20]. A lack of a robust and reproducible in vitro cultivation system for human noroviruses (HNoVs) has not been developed until recently, thereby hindering the development of effective interventions [21]. Therefore, our understanding of the HNoV life cycle was largely based on those surrogate viruses specifically the murine noroviruses (MNVs) [22]. Therapeutic candidates for FCV and MNV may be utilized for various FCV strains and HNoVs [13].

The cyclooxygenase (COX) enzymes, which convert arachidonic acid into prostaglandins (PGs), orchestrate a variety of homeostatic processes and participate in various pathophysiological conditions such as inflammation and immune responses [23–28]. Currently three isoforms of COXs have been identified, with COX-1 and COX-2 being the most studied [29]. COX-1 functions as a housekeeping isoform of COX and is expressed constitutively to perform functions such as control of renal blood flow, platelet aggregation, and provide protection against stomach ulcers [29]. COX-2 is activated in response to different extracellular or intracellular stimuli, which can lead to the accumulation of PGs including PGE$_2$ [30]. PGE$_2$ is commonly involved in cellular immunity and inflammation events, and serves as strong regulators of cell–cell interaction, cytokine production, antigen presentation, cell differentiation and survival, apoptosis, and cell migration [30].

Viral infections generally impose immunological pressure on their hosts that in turn can hinder their successful replication [31]. To evade this, viruses devise strategies to subvert cellular pathways for their own benefit such as via COXs/prostaglandin E$_2$ (PGE$_2$) signaling, which participates in the modulation of the host response to infection and the life cycle of several viruses [32–33]. Representatives from at least eleven different virus families are known to activate COXs/PGE$_2$ signaling or to enhance the expression levels of PGE$_2$: *Caliciviridae* [34], *Arteriviridae* [35], *Herpesviridae* [36], *Rhabdoviridae* [37], *Retroviridae* [38], *Picornaviridae* [39–40], *Flaviviridae* [41], *Orthomyxoviridae* [42–43], *Adenoviridae* [44], and *Paramyxoviridae* [45].

Some viruses including vesicular stomatitis virus (VSV) [37, 46], enterovirus 71 (EV71) [39–40, 47], dengue virus [41], hepatitis C virus (HCV) [48–49], Japanese encephalitis virus [46], influenza virus [42, 50], cytomegalovirus (CMV) [36, 51], herpes simplex virus type 1 (HSV-1) [52], and HSV-6 [53] are known to use the COX-2/PGE$_2$ signaling pathway for their benefit rather than COX-1/PGE$_2$ signaling pathway [33]. However, porcine reproductive and respiratory syndrome (PPRS) arterivirus has been shown to hijack the COX-1/PGE$_2$ signaling pathway and induce fever [35], and pseudorabies herpesvirus has been shown to use both COX-1 and COX-2/PGE$_2$ pathways for its successful replication [54]. In contrast, in vitro and/or in vivo treatment of PGE$_2$ reduces replication of hepatitis B virus [43, 55], adenoviruses [44], parainfluenza virus [56], and measles virus [45], suggesting an antiviral function of PGE$_2$ to these viruses. Moreover, the COXs/ PGE$_2$ signaling pathway or their final product PGE$_2$ has been shown to facilitate or inhibit the replication of viruses in the same family. For example, in the *Retroviridae* family, the COXs/PGE$_2$ signaling pathway and/or PGE$_2$ enhances the replication of bovine leukemia virus [38], as well as human T-cell leukemia virus-I [57] and III [58], but inhibits human
immunodeficiency virus-1 (HIV-1) in monocyte-derived macrophage [59]. It should be noted that treatment of PGE\(_2\) enhances the replication of HIV-1 in the CD4+ T-cell line MT-4 [60], indicating also that depending on the cells, the role of COXs/PGE\(_2\) signaling pathways is different in the same viral infection.

Previously, we reported that infection of PSaV strain Cowden induced strong COX-2/PGE\(_2\) signaling with only a transient COX-1/PGE\(_2\) signal during late stage infection [34]. Pharmacological inhibitors or siRNAs against COX-1 and COX-2 significantly reduced PSaV replication, which was restored by the addition of PGE\(_2\), indicating that COXs/PGE\(_2\) acts as a proviral signal [34]. However, the role of COXs/PGE\(_2\) signaling is unknown for other members within the Caliciviridae family. This prompts us to investigate whether other members of caliciviruses, in particular the FCV and MNV strains, use the COX-2/PGE\(_2\) signaling pathway in the regulation of their own replication. Here, we demonstrated that COX-2 expression was induced during FCV and MNV infections, thereby causing a surge in PGE\(_2\) levels. Furthermore, pharmacological inhibitors and siRNAs against COX-1 and COX-2 enzymes significantly reduced PGE\(_2\) production as well as MNV and FCV replication, which could be restored by the addition of PGE\(_2\). These results suggest that COX-2/PGE\(_2\) pathway has proviral effects for FCV and MNV replication.

**Materials and methods**

**Cells and viruses**

RAW264.7 mouse macrophage and Crandell Rees feline kidney (CRFK) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VI, USA) and were routinely grown in Dulbecco’s modified Eagle’s minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 \(\mu\)g/ml streptomycin. The FCV F9 strain was obtained from ATCC and was propagated in CRFK cells. The MNV strain CW-1 was a kind gift from Dr. H.W. Virgin, Washington University School of Medicine, USA. Cesium chloride (CsCl) density gradient ultracentrifugation was performed to purify each mass-cultured strain as described previously [61–62]. The viral titer for MNV and FCV strains was determined by median tissue culture infectious dose (TCID\(_{50}\)) in units per milliliter and immunofluorescence assay, respectively, as described below.

**Chemicals and antibodies**

NS-398 and SC-560 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Indomethacin and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO, USA). COX-1 and COX-2 siRNAs, which were comprised of three targets for each gene, and scrambled siRNA were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Synthetic PGE\(_2\) was from Tocris Bioscience (Ellisville, MO, USA). Polyclonal antibody against rabbit COX-2 and monoclonal antibody against mouse COX-1 were acquired from Abcam (Cambridge, MA, USA). Mouse monoclonal antibody against FCV capsid protein was from Santa Cruz Biotechnology, Inc. The rabbit polyclonal MNV VPg antibody was a kind gift from Dr. I. Goodfellow, Cambridge University, UK. The secondary antibodies used were horseradish peroxidase-conjugated goat immunoglobulin against rabbit IgG (Cell Signaling, Beverly, MA, USA) and mouse IgG (Santa Cruz), and fluorescein isothiocyanate (FITC)-conjugated goat immunoglobulin against rabbit IgG and mouse IgG (Jackson Immuno Research Laboratory, West Grove, PA, USA).

**Cytotoxicity assay**

The cytotoxicity test for the different chemicals used was carried out by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described previously [34, 63].
Briefly, monolayers of RAW264.7 and CRFK cells grown in 96-well plates were incubated for 24 h with different concentrations of chemicals. After removal of the medium and washing twice with phosphate buffered saline (PBS, pH 7.4), 200 μl of MTT solution was added in each well and incubated for 4 h at 37˚C in a CO2 incubator. Next, 150 μl of DMSO was added to each well and incubated for 10 min at room temperature. Optical density (OD) was determined in an enzyme-linked immunoabsorbent assay (ELISA) reader at 570 nm. Calculations for the percent cell viability was determine using the following formula: \[ \frac{(OD_{\text{sample}} - OD_{\text{blank}})}{(OD_{\text{control}} - OD_{\text{blank}})} \times 100 \]. Nontoxic concentrations of chemicals were utilized in this study.

**Treatment of cells with inhibitors**

The inhibitors and chemicals used in this study were diluted in DMSO to a stock concentration of 10 mM and were subsequently diluted in media to make working solutions. Monolayers of RAW264.7 and CRFK cells grown in 6- or 12-well plates were treated with chemicals or inhibitors as described previously [34]: mock-treatment, pre-treatment, post-treatment, and pre-post-treatment. Briefly, confluent cells pretreated with various concentrations of the inhibitors for 24 h were infected with MNV (MOI, 1 TCID50/ml) or FCV (MOI, 1 FFU/ml) strains for the pre-treatment groups. For the post-treatment groups, cells were adsorbed with MNV (MOI, 1 TCID50/ml) or FCV (MOI, 1 FFU/ml) strains and then treated with different concentrations of inhibitors. For the pre-post-treatment groups, cells were pretreated with different concentrations of inhibitors for 24 h, adsorbed with MNV (MOI, 1 TCID50/ml) or FCV (MOI, 1 FFU/ml) strains, and treated again with the same concentration of inhibitors described above.

**Plasmid constructs**

The cDNA from a partial part of the polymerase of the FCV F9 strain and a part of the N-terminal of the open reading frame (ORF) 1 of the MNV strain were amplified by conventional PCR using the primers listed in Table 1. The DNA fragments were gel purified using the Wizard® SV Gel and PCR Clean-Up system (Promega, Fitchburg, Wisconsin, USA) and ligated to pGEM-Teasy vector (Promega). Samples were transformed in homemade DH5α and positive colonies were picked by white and blue screening. The selected colonies were grown in LB-medium containing ampicillin. The plasmids were purified using Hybrid-Q Plasmid Rapidprep kit (GeneAll, Songpa-gu, Seoul, South Korea) and concentrations were determined by spectrophotometry (BioPhotometer plus, Eppendorf, Hamburg, Germany). The plasmids for FCV and MNV strains were named pTA-FCV and pTA-MNV-1, respectively.

**RNA extraction**

Mock- or virus-infected, mock- or inhibitor-treated, or siRNA-transfected cells were washed thrice with cold PBS, scraped, and collected in clean microtubes. Harvested samples were centrifuged at 2,469 × g for 10 min, and then total RNA was extracted using the PureLink RNA minikit (Ambion Life Technologies, Carlsbad, CA, USA) following the manufacturer’s instructions. To quantify the genome copy numbers of FCV or MNV strains, the cells treated with inhibitors, infected with each strain, or transfected with each siRNA described above were freeze-thawed three times, and cell debris were removed by centrifugation at 2,469 × g at 10 min at 4˚C. Samples were immediately processed or stored at -80˚C until use. Total RNA was isolated from supernatants using a Viral RNA extraction kit (Bionner, Daejeon, South Korea) following the manufacturer’s instructions. Concentrations of extracted RNAs were calculated by spectrophotometry at 260 nm using the BioPhotometer plus (Eppendorf).
Quantitative real-time PCR

A one-step real-time RT-PCR (qRT-PCR) assay with primer pairs specific to the polymerase of FCV and ORF1 of MNV was performed as described previously [61, 64–66]. The primer pairs used are listed in Table 1. Briefly, total RNA was isolated as described above from harvested samples that were subjected to three times freeze-thaw cycles. All reactions were carried out using a Corbett Research Rotor-Gene Real-time Amplification system (Corbett Research, Mortlake, Australia) and SensiFast™ SYBR® Lo-ROX One Step Kit (Bioline, London, UK). Next, 25 μl qRT-PCR reactions were prepared, which were composed of 5 μl RNA template, 10 μl SensiFast one-step mixture, 1 μl of forward and reverse primers (final concentration of each primer: 10 pmole), 0.2 μl reverse transcriptase, 0.4 μl of RiboSafe RNase inhibitor, and 7.4 μl of RNase free water. The amplification profile for FCV was as follows: reverse transcription at 45˚C for 10 min, polymerase activation at 95˚C for 2 min, and 45 cycles of amplification consisting of denaturation at 94˚C for 10 s, primer annealing at 55˚C for 20 s, and extension at 72˚C for 10 s. For MNV-1, the reverse transcription was carried out at 45˚C for 10 min, followed by polymerase activation at 95˚C for 2 min, an initial denaturation at 95˚C for 5 min, and 45 cycles of amplification consisting of denaturation at 94˚C for 15 s, primer annealing at 57˚C for 30 s, and extension at 72˚C for 20 s. The copy numbers of the FCV and MNV-1 genes were calculated using 10-fold dilutions of a known concentration of in vitro transcribed complementary RNA using the pTA-FCV and pTA-MNV-1 plasmids to make the standard curve. Quantifications of RNA from samples were calculated using the Rotorgene 3000 (Corbett Research, Mortlake, Australia).

To determine the expression levels of COX genes in mock-, virus-, chemical-, or siRNA-treated samples, cells were harvested and total RNA were extracted as described above. RNA concentrations were determined, and cDNA was prepared using 1 μg of RNA and reverse transcribed using random hexamers (Roche, Basel, Switzerland). The specific primer pairs for qPCR were designed based on the published sequences for COX-1 and COX-2 as listed in Table 1. Reactions were carried out in a total volume of 25 μl containing 10 pmole of forward and reverse primers, cDNA, and TOPreal qPCR 2X Premix (Enzynomics, Daejon, South Korea).

Table 1. Oligonucleotides used in this study.

| Target gene | Sequence (5'-3') | Region (nt) | Size (bp) | Reference | Accession no. |
|-------------|------------------|-------------|-----------|-----------|---------------|
| MNV-1 (ORF1) (RT-PCR) | F: TGCCGAAACTGACCTTGGG | 6–25 | 1015 | This study | DQ285629.1 |
| | R: ATGAACTCCTTCTTTGCCGGA | 996–1015 | | | |
| FCV (RdRp) (RT-PCR) | F: CCGTCGCAAAAAACCTCTCA | 3901–3920 | 4661–4680 | This study | M86379.1 |
| | R: TCACTAATTACATGGCCCTAA | 4661–4680 | | | |
| MNV-1 (ORF1) (qPCR) | F: GCAGGAAGCTCAGCAGCG | 39–58 | 139 | Taube et al., 2009 | DQ285629.1 |
| | R: TCACTAATTACATGGCCCTAA | 160–177 | | | |
| FCV (RdRp) (qPCR) | F: AATTTTACCTCCGAAAAACCTCT | 4041–4060 | 4261–4280 | This study | M86379.1 |
| | R: GGAAAGAAGTTAAGTGAGGGA | 4261–4280 | | | |
| Murine COX-1 | F: TTACCCCTGAGATGAGGAGT | 1895–1914 | 2011–2030 | This study | NM_008969 |
| | R: GGTTTGCTGCTGTTGGCCATT | | | | |
| Murine COX-2 | F: CTTCGGGAGCAGACACAAAGGT | 1067–1086 | 1202–1221 | This study | NM_011198.4 |
| | R: CACCTGAGCGGTGATTACCTTT | 1202–1221 | | | |
| Feline COX-1 | F: GCAGTTGAGCCGTGTTAACCTCC | 1134–1153 | 1282–1300 | This study | XM_006939439 |
| | R: CCGGAGTACAGCTACGGG | | | | |
| Feline COX-2 | F: AAAAACTGGGAGAATCCCTGGA | 32–51 | 188–207 | This study | EF036473 |
| | R: CTTCGCTGCTCCTACAGCATGC | 188–207 | | | |
| Murine beta-actin | F: TATAAAACCCCGTGGGGCCA | 1–19 | 63 | This study | NM_007393 |
| | R: CTCTGACGTCTGTCTGGT | 63–83 | | | |
| Feline beta actin | F: TCTCGGGGATGAAGCTTGGTTG | 609–628 | 690–709 | This study | AB051104 |
| | R: TTACTCCTAACAACGGGGTCGT | | | | |

https://doi.org/10.1371/journal.pone.0200726.t001
The amplification of COX-1 and COX-2 were as follows: initial denaturation at 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 10 s, primer annealing at 57˚C for 20 s, and extension at 72˚C for 10 s. The relative expressions of COX-1 and COX-2 were calculated via $2^{-\Delta\Delta CT}$ using the Rotorgene 3000® software (Corbett Research, Mortlake, Australia) as described previously [34].

Detection of PGE$_2$ in cell culture supernatant by ELISA

Levels of PGE$_2$ were determined via the PGE$_2$ EIA kit (Cayman Chemical, Ann, Arbor, MI, USA) following the manufacturer’s instructions for clarified supernatants collected in different time points from the cells mock-infected or infected with each virus, mock-treated or treated with each chemical, or scrambled siRNA-transfected or transfected with siRNAs against COX-1 or COX-2. Using an ELISA reader, the absorbance was read at 405 nm and concentrations of PGE$_2$ were calculated in comparison to a standard curve.

TCID$_{50}$ assay

The median tissue culture infectious dose (TCID$_{50}$) of MNV and FCV strains in the samples obtained from the above experiments were determined as described previously [34]. Briefly, 10-fold serial dilutions of clarified supernatants were prepared. Confluent RAW264.7 and CRFK cells grown on 96-well plates were inoculated with 200 μl of each diluted sample and then incubated at 37˚C in a 5% CO$_2$ incubator. After 3–5 days postinfection, viral titers were calculated using the Reed and Muench method [67] and expressed as TCID$_{50}$/ml.

Silencing of COX-1 and COX-2 genes by transfection of siRNA

The siRNAs targeting COX-1 and COX-2 genes or scrambled siRNA were transfected to confluent CRFK and RAW 264.7 cells grown on 6- or 24-well plates using Lipofectamine 3000® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions [34]. Cell were then mock-infected or infected with FCV (MOI, 1 FFU/ml) and MNV (MOI, 1 TCID$_{50}$/ml) strains. Cells were subjected to qPCR, TCID$_{50}$/ml, and Western blot analyses at the appropriate time points.

Cell lysate preparation and Western blot analysis

Cells from the above experiments were washed, harvested, and lysed at different time points using a cell extraction buffer (Invitrogen) supplemented with protease and phosphatase inhibitors (Roche). Denatured cell lysates were resolved in sodium dodecyl sulfate (SDS) polyacrylamide gels and then transferred to nitrocellulose blotting membranes (Amersham Protran, GE Healthcare Life Science, Germany). Membranes were immunoblotted with primary antibodies against COX-1, COX-2, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), MNV VPg, or FCV capsid. Secondary antibodies specific for rabbit or mouse IgG were added for 1 h at room temperature and were developed using an enhanced chemiluminescence reaction kit (DoGen, Nowon-gu, Seoul, South Korea). Images were captured on the Davinch-Western imaging system (Young Ltd., Kang-Nam, Seoul, South Korea). Samples were normalized to the corresponding GAPDH level in the same samples. The intensity of COX-1 and COX-2 proteins relative to GAPDH was determined by densitometric analysis.

Immunofluorescence assay

The viral titer for FCV F9 strain was determined by immunofluorescence assays as described previously [12, 13]. Briefly, confluent CRFK cells grown on 96-well plates were inoculated with
200 μl of each diluted sample and then incubated at 37˚C in a 5% CO₂ incubator. After 4 hpi, cells were fixed with cold acetone. Cells were washed with PBS containing new fetal bovine serum (PBS-FBS) before incubating with anti-FCV capsid (1:100 dilution) overnight at 4˚C. The cells were washed three times with cold PBS, and then FITC-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA) secondary antibody was added and incubated for 1 h at room temperature. Afterwards, slides were washed three times with cold PBS and mounted with 60% glycerol in PBS (pH 8.0). FCV titer was calculated using the Reed and Muench method [67] and expressed as fluorescence focus unit (FFU)/ml.

Infection inhibitory effects of each inhibitor or siRNA were determined by immunofluorescence assays as described previously [68]. Briefly, cells grown on 8-well chamber glass slides were treated with various inhibitors or transfected with siRNAs before or after infection of FCV (1 FFU/ml) or MNV (MOI, 1 TCID₅₀/ml) strains as mentioned above. Then, cells were washed three times with cold PBS before being fixed with 4% formaldehyde in PBS. Cells were permeabilized with 0.02% Triton X-100, incubated at room temperature for 10 min, washed with PBS containing new fetal bovine serum (PBS-FBS) before incubating with anti-MNV VPg (1:100 dilution) or anti-FCV capsid (1:100 dilution) overnight at 4˚C. The cells were washed three times with cold PBS, and then anti-rabbit or anti-mouse Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) secondary antibodies were added. Afterwards, slides were mounted with SlowFade Gold antifade reagent (Life Technologies, Eugene, OR, USA) containing DAPI (4’,6-diamidino-2-phenylindole) solution for nuclear staining and was visualize using the LSM 510 confocal microscope and analyzed using LSM software (Carl Zeiss, Oberkochen, Germany).

**Results**

**FCV and MNV infections induce COX-2 expression that leads to the production of PGE₂**

We previously reported that infection of LLC-PK cells with PSaV strain Cowden strongly activated the COX-2/PGE₂ signaling pathway but transiently induced COX-1/PGE₂ signaling pathway during the late stage of infection [34]; hence, we examined whether both FCV and MNV strains also have the ability to activate the COXs/PGE₂ signaling pathway during their replication. To investigate this, we first evaluated the influence of FCV and MNV infections on COX gene and protein expressions. Expression levels of COX-2 mRNA and protein gradually increased from 1 h post-infection (hpi) (Fig 1A and 1C) in parallel with increased FCV viral RNA synthesis (Fig 1B), while COX-1 protein levels remained unchanged (Fig 1A and 1C). Similarly, the time-dependent increase in the expression of COX-2 mRNA and protein levels was observed in association with an increase in MNV mRNA level starting at 4 hpi (Fig 2A–2C). The expression level of COX-1 mRNA and protein was also unaffected during MNV infection (Fig 2A and 2C). Since PGE₂ is one of the main products of the COX enzymes [29], we also assessed the expression levels of PGE₂ during FCV and MNV infections. Concurrent with the increased COX-2 levels during MNV and FCV infections, the production of PGE₂ was also elevated in a time-dependent manner starting from 1 hpi for FCV (Fig 1D) and from 4 hpi for MNV (Fig 2D).

To further confirm the correlation of increased PGE₂ with the FCV- and MNV-mediated induction of COX-2, the influence of selective and nonselective COX inhibitors on PGE₂ expression was investigated. Non-toxic doses were used for this study as determined by the MTT assay (S1 Fig). The selective COX-1 inhibitor SC-560, selective COX-2 inhibitor NS-398, and nonselective COX-1 and -2 inhibitor indomethacin hampered FCV mediated-PGE₂ induction in a dose-dependent manner when added after the removal of the virus inoculum (post-treatment) or added before and after the virus adsorption step (pre-post-treatment) (Fig 3A–3C). Similarly,
addition of COX inhibitors after removal of the MNV inoculum or during the entire course of the MNV infection reduced PGE$_2$ levels (Fig 3D–3F). However, the pretreatment of cells and consequent removal of inhibitors before FCV or MNV infection did not lower PGE$_2$ levels due to the reversible nature of the inhibitors (Fig 3A–3F).

To further corroborate the influence of COX genes in the production of PGE$_2$ during FCV and MNV infections, the effects of siRNAs were also examined. RAW 264.7 and CRFK cells transfected with siRNAs against COX-1 or COX-2 genes showed a reduction in the expression levels of their corresponding target genes (Fig 3G and 3H). Transfection of siRNAs targeting COX-1 or COX-2 in RAW 264.7 and CRFK cells following FCV and MNV infections, respectively, significantly reduced the amount of PGE$_2$ released (Fig 3G and 3H). These results confirmed that induction of COX-2, together with the basal expression of COX-1, accounted for the increase in PGE$_2$ in FCV and MNV-infected cells.

**Inhibition of both COX enzymes reduce FCV and MNV replication**

To assess the effect of COX stimulation on the replications of FCV and MNV strains, we assessed the impact of COX inhibitors on FCV and MNV replication. RAW 264.7 and CRFK
cells were pre-treated (Pre), post-treated (Post), or pre-post-treated (Pre-Post) with COX inhibitors, and viral replication was monitored at 8 hpi for FCV and 24 hpi for MNV by examining the viral titers and RNA levels. The selective COX-1 inhibitor SC-560 reduced the levels of infectious virus and RNA ~3 log_{10} for FCV (Fig 4A and 4B) and by ~4 log_{10} for MNV (Fig 5A and 5B) when added after infection (post-treatment) or maintained throughout the virus infection (pre-post-treatment). Conversely, the addition of NS-398 (selective COX-2 inhibitor) following the removal of the virus inoculum (post-treatment) or during the entire progression of infection (pre-post-treatment) caused a more significant reduction in FCV (~4.5 log_{10}) in both infectious virus and viral RNA (Fig 4C and 4D), while MNV infectious viral titer and genome copy numbers were reduced ~3 log_{10} (Fig 5C and 5D). Indomethacin, a nonselective COX inhibitor, showed more significant effects on MNV infection, leading to a ~5 log_{10} reduction in virus yield and RNA synthesis (Fig 5E and 5F), while FCV infection elicited a ~3 log_{10} decrease in infectious viral titer and genome copy numbers (Fig 4E and 4F) when added after virus adsorption or maintained throughout the course of the infection. There was no significant effect on FCV or MNV replication in cells pretreated with COX inhibitors (Figs 4A–4F and 5A–5F). We also assessed the effect of COX-specific siRNAs on FCV and MNV replication. FCV genome copy numbers and titers were more strongly reduced (~4 log_{10}) in cells

Fig 2. COX-2 mRNA and protein levels increase upon murine norovirus (MNV) infection with subsequent production of PGE_{2}. (A and B) Cultured RAW264.7 cells were mock-infected or infected with MNV (MOI, 1 TCID_{50}/ml) for the indicated time points, and the expression of COX-1 and COX-2 mRNAs, and MNV viral RNA were determined by quantitative real time PCR. The mRNA expression levels of COX-1 and COX-2 were normalized to β-actin mRNA and are presented as a fold induction as compared with the mock-infected cells. (C) Monolayers of RAW264.7 cells were infected with or without MNV (MOI, 1 TCID_{50}/ml) for the indicated time points, and the levels of the COX-1, COX-2, and GAPDH proteins were analyzed by Western blot analysis. GAPDH was used as a loading control. The intensity of each target protein relative to GAPDH was determined by densitometric analysis and is indicated above each lane. (D) Cell culture supernatants harvested from the cells infected with or without MNV at the indicated time points were checked for the presence of PGE_{2} by ELISA. The levels of PGE_{2} in the supernatants were compared between mock- and MNV-infected groups. The presented data are depicted as means and standard errors of the mean from three different experiments. Statistical analyses were performed using one-way analysis of variance. **p < 0.0001.
transfected with siRNA against COX-2 than that in cells transfected with COX-1 siRNA (~2 log₁₀) (Fig 4G and 4H). Transfection of COX-1- or COX-2-specific siRNAs resulted in similar substantial reduction in MNV replication, causing a ~4 log₁₀ decrease in infectious viral titer and RNA levels (Fig 5G and 5H).

To further assess the effect of COX inhibitors on FCV and MNV replication, we also analyzed viral protein levels in the pre- and post-treatment groups. Consistent with the above results, a reduced production of FCV capsid protein was observed with the post-treatment of COX inhibitors in a dose-dependent manner, in which NS398 showed stronger anti-FCV effects against other inhibitors (Fig 6A). The expression level of MNV VPg protein decreased

https://doi.org/10.1371/journal.pone.0200726.g003
Fig 4. Inhibition of COX isoforms results in a dramatic reduction in feline calicivirus (FCV) progeny yield. (A–F) CRFK cells were pretreated (Pre), post-treated (Post), or pre-post-treated (Pre-Post) with non-cytotoxic doses of SC-560, NS-398, and indomethacin. At 8 h post-infection (hpi) with FCV (MOI, 1 FFU/cell), the viral titer and genome copy number were determined by TCID₅₀/ml and quantitative real-time PCR (qRT-PCR). The inhibitory effects of each drug on virus titer or genome copy number were compared between mock- and drug-treated groups. (G and H) COX-1, COX-2, or scrambled (Scram) siRNAs were transfected in CRFK cells before infection with FCV (MOI, 1 FFU/cell). The samples were harvested at 8 hpi, and then the viral titer and genome copy number were determined by TCID₅₀/ml (G) and qRT-PCR (H) analyses. Three independent experiments were conducted and presented as...
due to the COX inhibitors in a dose-dependent manner, particularly with the post-treatment of indomethacin (Fig 7A). Transfection of COX-1 and COX-2 siRNAs resulted in lower protein induction in both FCV- and MNV-infected cells (Figs 6B and 7B). Furthermore, treatment of CRFK cells with NS-398 or transfection with COX-1 and COX-2 specific siRNAs caused a significant decreased in the number of FCV antigen-positive cells (Fig 6C). Similarly, a reduced number of MNV antigen-positive cells was also observed in RAW264.7 cells treated with NS-398 or transfected with COX-1 or COX-2 specific siRNAs (Fig 7C). Together, these results suggested that both COX-1 and COX-2 augment FCV and MNV replication possibly in relation with the increased levels of PGE$_2$.

**Addition of PGE$_2$ restores the inhibitor effect of COXs on FCV and MNV replication**

To further study the proviral effect of COXs/PGE$_2$ induction during FCV and MNV infections, we assessed whether the addition of exogenous PGE$_2$ restores the inhibitory effect of COX inhibitors on viral replication. The selective COX-2 inhibitor NS-398 was used for FCV, while the nonselective inhibitor indomethacin was used for MNV, both of which showed strong inhibitory effect compared with other COX inhibitors. Non-cytotoxic doses of COX-inhibitors in combination with exogenous PGE$_2$ were used in this experiment. The addition of PGE$_2$ lead to the restoration of both FCV and MNV progeny production and viral RNA levels in a dose-dependent manner (Fig 8A–8D). Collectively, these results confirmed that PGE$_2$, the final product of both COX enzymes, mediated the proviral effects on FCV and MNV replication.

**Discussion**

Depending on the viruses, the COXs/PGE$_2$ signaling pathway was used differently: COX-1/PGE$_2$ for PRRS arterivirus [35], COX-2/PGE$_2$ for many viruses [36, 37, 39–42, 46–49, 50–53], or both for pseudorabies herpesvirus [54]. In the present study, both FCV and MNV strongly activated the COX-2/PGE$_2$ pathway from an early replication time point. These results are different from our previous finding where the PSaV strain Cowden, belonging to the same *Caliciviridae* family, induced late activation of the COX-2/PGE$_2$ signaling pathway [34]. This suggested that the activation time of the COX-2/PGE$_2$ signaling pathway was different even in the same *Caliciviridae* family. In addition, the PSaV Cowden strain transiently activated COX-1/PGE$_2$ signaling during the later stage of infection [34]. Interestingly, no increases in the COX-1 mRNA and protein levels were observed during the entire FCV and MNV infection. However, silencing of COX-1 by specific siRNAs as well as the inhibition of COX-1 by the specific inhibitor SC-560 decreased the production of PGE$_2$ and replication of both viruses. Although the detailed mechanism of these results is unknown, it is presumed that the inhibition of the basal expression level of COX-1 by its specific inhibitor and siRNA suppressed PGE$_2$ production and thereby the replication of both viruses. Based on these results, it could be concluded that unlike the PSaV-induced late activation of both COX-1 and COX-2/PGE$_2$ signaling pathways, both FCV and MNV activate only COX-2/PGE$_2$ signaling pathway from early replication, but COX-1 might be an important factor for the successful replication of FCV and MNV.

In relation to the virus replication, the COX/PGE$_2$ signaling pathway can have proviral [36, 37, 41, 42, 45, 50–52, 54, 55, 57, 58, 69], or antiviral [33, 43–45, 55, 56, 59] effects. In the present
Fig 5. Murine norovirus (MNV) infection is hampered by COXs inhibitors. (A–F) Raw264.7 cells were pretreated (Pre), post-treated (Post), or pre-post-treated (Pre-Post) with non-cytotoxic doses of SC-560, NS-398, or indomethacin. At 24 h post-infection (hpi) with MNV (MOI, 1 TCID50/ml), viral titer and genome copy number were determined by TCID50/ml and quantitative real-time PCR (qRT-PCR) analyses. The inhibitory effects of each drug on the viral titer or genome copy number were compared between mock- and
study, the inhibition or silencing of COX-2 reduced replication of FCV and MNV. Moreover, reduced viral replication by COX inhibitors was restored by addition of PGE$_2$. Similar results have been recently reported in a PSaV infection study [34]. These data indicate that like PSaV [34], FCV- and MNV-induced activation of the COX-2/PGE$_2$ signaling pathway acts as a pro-viral mechanism for the replication of FCV and MNV.

Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting COX enzymes are one of the most widely prescribed drugs due to their analgesic effects and their potent anti-inflammatory and anti-pyretic properties in the western world [26, 70]. NSAIDs have been reported as potential therapeutic drugs for some viral infection. For example, pharmacological use of a COX-2 inhibitor in combination with neuraminidase inhibitors enhanced the survival of mice infected with H5N1 influenza [71]. The selective COX-2 inhibitor NS-398 was shown to protect mice from succumbing to dengue virus-2 infection [41]. In this study, we determined the potency of different COX inhibitors against FCV and MNV infections. In the FCV infection, the COX-2 selective inhibitor NS398 exerted ~4 log$_{10}$ suppression in the FCV titer compared to other inhibitors. Among the COX inhibitors tested against MNV, indomethacin, a nonselective COX inhibitor, showed stronger anti-MNV effects than other inhibitors, leading to a ~5 log$_{10}$ decrease in MNV titer. These results suggest that COX inhibitors are potential

![Fig 6. Effects of COX inhibitors or siRNAs on feline calicivirus (FCV) replication.](https://doi.org/10.1371/journal.pone.0200726.g006)
candidates for the treatment of FCV infections, which are particularly serious problems for cats [12, 14]. Future studies are needed to determine whether in vivo treatments with COX inhibitors are effective in treating FCV and MNV infections.

Nitric oxide (NO) has been shown to exert antiviral effects during virus infections [72–76]. It has also been shown that the COX/PGE\textsubscript{2} signaling pathway also regulates inducible nitric oxide synthase, the enzyme responsible for the production of NO [77]. In vitro and in vivo vesicular stomatitis virus infection has been shown to activate the COX-2/PGE\textsubscript{2} signaling pathway, which in turn restricts NO production [37, 46]. In the same way, we demonstrated that PSaV-induced activation of COX-2/PGE\textsubscript{2} signaling pathway inhibited NO production [34] to favor PSaV replication. A similar response is expected in FCV and MNV infections, which is the ongoing goal of future studies.

In conclusion, our results denote a crucial role for the COX-2/PGE\textsubscript{2} signaling pathway in the successful replication of FCV and MNV by creating a cellular environment suitable for...
efficient growth for both viruses. Furthermore, our results indicate that NSAIDs, pharmaco-
logical inhibitors against COX-1 and -2 enzymes, can be used as therapeutic drugs for FCV,
MNV, and other members such as human noroviruses.

Supporting information
S1 Fig. Cytotoxic assays for different chemicals used in the study. RAW264.7 (A–D) and
CRFK (E–H) cells were treated with different concentrations of the selective COX-1 inhibitor
SC-560, selective COX-2 inhibitor NS-398, nonselective COX inhibitor indomethacin (Indo),
and exogenous prostaglandin E2 (PGE$_2$). A MTT assay was performed to determine the non-
cytotoxic doses to use in this study.

Fig 8. Addition of exogenous prostaglandin E2 can compensate for COX-induced inhibition of feline calicivirus
(FCV) and murine norovirus (MNV) replications. (A–D) CRFK cells and RAW264.7 were infected with FCV (MOI,
1 FFU/ml) and MNV (MOI, 1 TCID$_{50}$/ml), respectively, and then treated with nontoxic doses of indomethacin
and NS-398 for MNV and FCV, respectively. Two doses of exogenous PGE$_2$, 5 or 50 μM for MNV, and 2 μM or 20 μM
for FCV, were then added in the maintenance media, and samples were harvested at 8 h post-infection (hpi) for FCV
and 24 hpi for MNV. Viral titer and viral genome copy numbers were determined by TCID$_{50}$ and quantitative real
time PCR analyses and compared between mock- and drug-treated groups. The data presented are means
and standard errors of the mean from three different experiments. Statistical analysis was performed using one-way
analysis of variance. ** $p < 0.001$.

https://doi.org/10.1371/journal.pone.0200726.g008

Acknowledgments
We thank Dr. Ulrich Desselberger (Department of Medicine, University of Cambridge, UK)
for insightful comments on this manuscript. We thank Dr. H.W. Virgin (Washington University
School of Medicine) for his generous gift of MNV CW-1 strain and Dr. I Goodfellow
(Cambridge University) for his kind gift of MNV VPg antibody.

Author Contributions
Conceptualization: Mia Madel Alfajaro, Sang-Ik Park, Kyoung-Oh Cho.
Data curation: Mia Madel Alfajaro, Jun-Gyu Park, Ji-Yun Kim, Mahmoud Soliman, Yeong-Bin Baek, Mun-II Kang.

Formal analysis: Mia Madel Alfajaro, Eun-Hyo Cho, Mun-II Kang, Sang-Ik Park, Kyoung-Oh Cho.

Funding acquisition: Mun-II Kang, Sang-Ik Park, Kyoung-Oh Cho.

Investigation: Mia Madel Alfajaro.

Methodology: Mia Madel Alfajaro, Eun-Hyo Cho, Jun-Gyu Park, Ji-Yun Kim, Mahmoud Soliman, Yeong-Bin Baek, Mun-II Kang, Kyoung-Oh Cho.

Project administration: Sang-Ik Park, Kyoung-Oh Cho.

Writing – original draft: Mia Madel Alfajaro.

Writing – review & editing: Sang-Ik Park, Kyoung-Oh Cho.

References
1. Green KY. Caliciviridae: The Noroviruses. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, et al. editors. Fields Virology, 6th ed, Lippincott Williams & Wilkins; 2014 pp 582–608.
2. Clarke IN, Estes MK, Green KY, Hansman GS, Knowles NJ, Koopmans MK, et al. Caliciviridae. In: Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses. Ed: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Elsevier; 2012. pp 977–986.
3. Farkas T, Sestak K, Wei C, Jiang X. Characterization of a rhesus monkey calicivirus representing a new genus of Caliciviridae. J Virol. 82(11):5408–5416. https://doi.org/10.1128/JVI.0070-08 PMID: 18385231.
4. Wolf S, Reetz J, Otto P. Genetic characterization of a novel calicivirus from a chicken. Arch Virol. 2001; 156(7):1143–1150. https://doi.org/10.1007/s00705-011-0964-5 PMID: 21404111.
5. Wolf S, Reetz J, Hoffmann K, Gründel A, Schwarz BH, Hünel I, et al. Discovery and genetic characterization of novel caliciviruses in German and Dutch poultry. Arch Virol. 2012; 157(8):1499–1507. https://doi.org/10.1007/s00705-012-1326-7 PMID: 22580496.
6. Day JM, Ballard LL, Duke MV, Scheffler BE, Zsak L. Metagenomic analysis of the turkey gut RNA virus community. Virol J. 2010; 7:313. https://doi.org/10.1186/1743-422X-7-313 PMID: 21073719.
7. Liao Q, Wang X, Wang D, Zhang D. Complete genome sequence of a novel calicivirus from a goose. Arch Virol. 2014; 159(9):2529–2531. https://doi.org/10.1007/s00705-014-2083-6 PMID: 24756346.
8. Mikalsen AB, Nilson P, Frøystad-Saugen M, Lindmo K, Eliassen TM, Rode M, et al. Characterization of a novel calicivirus causing systemic infection in Atlantic salmon (Salmo salar L.): proposal for a new genus of Caliciviridae. PLoS One. 2014; 9(9):e107132. https://doi.org/10.1371/journal.pone.0107132 PMID: 25203050.
9. Wang F, Wang M, Dong Y, Zhang B, Zhang D. Genetic characterization of a novel calicivirus from a goose. Arch Virol. 2017; 162(7):2115–2118. https://doi.org/10.1007/s00705-017-3302-8 PMID: 28289976.
10. L’Homme Y, Sansregret R, Plante-Fortier E, Lamontagne AM, Ouardani M, Lacroix G, et al. Genomic characterization of swine caliciviruses representing a new genus of Caliciviridae. Virus Genes. 2009; 39(1):66–75. https://doi.org/10.1007/s11262-009-0360-3 PMID: 19396587.
11. Radford AD, Coyne KP, Dawson S, Porter CJ, Gaskell RM. Feline calicivirus. Vet Res. 2007; 38(2):319–335. https://doi.org/10.1051/vetres:2006056 PMID: 17296159.
12. Foley J, Hurley K, Pesavento PA, Poland A, Pedersen NC. Virulent systemic feline calicivirus infection: local cytokine modulation and contribution of viral mutants. J Feline Med Surg. 2006; 8(1):55–61. https://doi.org/10.1016/j.jfms.2005.08.002 PMID: 16213763.
13. Kim Y, Chang KO. Fexaramine as an entry blocker for feline caliciviruses. Antiviral Res. 2018; 152:76–83. https://doi.org/10.1016/j.antiviral.2018.02.009 PMID: 29454892.
14. Pesavento PA, Chang KO, Parker JS. Molecular virology of feline calicivirus. Vet Clin North Am Small Anim Pract. 2008; 38(4):775–786. https://doi.org/10.1016/j.cvsm.2008.03.002 PMID: 18501277.
15. Jeong C, Park SI, Park SH, Kim HH, Park SJ, Jeong JH, et al. Genetic diversity of porcine sapoviruses. Vet Microbiol. 2007; 122(3–4):246–257. https://doi.org/10.1016/j.vetmic.2007.02.008 PMID: 17382492.
16. Park SI, Jeong C, Kim HH, Park SH, Park SJ, Hyun BH, et al. Molecular epidemiology of bovine noroviruses in South Korea. Vet Microbiol. 2007; 124(1–2):1235–133. https://doi.org/10.1016/j.vetmic.2007.03.010 PMID: 17466472

17. Park SI, Jeong C, Park SJ, Kim HH, Jeong YJ, Hyun BH, et al. Molecular detection and characterization of unclassified bovine enteric calciviruses in South Korea. Vet Microbiol. 2008; 130(3–4):371–379. https://doi.org/10.1016/j.vetmic.2008.01.017 PMID: 18387758

18. Ayukekong JA, Mesumbe HN, Oyero OG, Lindh M, Berdstrom T. Role of noroviruses as aetiological agent of diarrhoea in developing countries. J Gen Virol. 2015; 96(8):1983–1999. https://doi.org/10.1099/vir.0.00194 PMID: 26002299

19. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol. 2009; 44(1):1–8. https://doi.org/10.1016/j.jcv.2008.10.009 PMID: 19084472

20. Scherk MA, Ford RB, Gaskell RM, Hartmann K, Hurley KF, Lappin MR, et al. AAFP Feline Vaccination Advisory Panel Report. J Feline Med Surg. 2013; 15(9):1095–1054. https://doi.org/10.1177/1098612X13500429 PMID: 23966005

21. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016; 353(6306):1387–1393. https://doi.org/10.1126/science.aaf5211 PMID: 27562956

22. Wobus CE, Thackray LB, Virgin HW 4th. Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol. 2006; 80(11):5014–5012. https://doi.org/10.1128/JVI.02346-05 PMID: 16698919

23. Carey MA, Germolec DR, Langenbach R, Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids. 2003; 69(2–3):157–162. PMID: 12895598

24. Carey MA, Germolec DR, Bradbury JA, Gooch RA, Moorman MP, Flake GP, Langenbach R, Zeldin DC. Accentuated T helper type 2 airway response after allergen challenge in cyclooxygenase-1-/- but not cyclooxygenase-2-/- mice. Am J Respir Crit Care Med. 2003; 167(11):1509–1515. https://doi.org/10.1164/rccm.200211-1338OC PMID: 12626351

25. Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol. 2005; 175(10):6878–6884. PMID: 16272346

26. Carey MA, Bradbury JA, Rebollosa SB, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in the influenza A viral infection in mice. PLoS One. 2010; 5(7):e11610. https://doi.org/10.1371/journal.pone.0011610 PMID: 20657653

27. Rocca B, Spain LM, Pure E, Langenbach R, Patrone C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999; 103(10):1469–1477. https://doi.org/10.1172/JCI64400 PMID: 10330429

28. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97–120. https://doi.org/10.1146/annurev.pharmtox.38.1.97 PMID: 9597150

29. Gandhi J, Khera L, Gaur N, Paul C, Kaul R. Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis. Front Microbiol. 2017; 8:538. https://doi.org/10.3389/fmicb.2017.00538 PMID: 2800769

30. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012; 188(1):21–28. https://doi.org/10.4049/jimmunol.11011029 PMID: 22187483

31. Zheng J, Perlman S. Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host. Curr Opin Virol. 2018; 28:43–52. https://doi.org/10.1016/j.coviro.2017.11.002 PMID: 29172107

32. Paul AG, Chandran B, Sharma-Walia N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. Transl Res. 2013; 162(2):77–92. https://doi.org/10.1016/j.trsl.2013.03.004 PMID: 23567332

33. Steer SA, Corbett JA. 2003. The role and regulation of COX-2 during viral infection. Viral Immunol. 2003; 16(4):447–460. https://doi.org/10.1089/08828240371926283 PMID: 14733733

34. Alfajaro MM, Choi JS, Kim DS, Seo JY, Kim JY, Park JG, et al. Activation of COX-2/PGE2 pathway enhances FCV and MNV replication. J Virol. 2017; 91(3):e01656–16. https://doi.org/10.1128/JVI.01656-16 PMID: 27881647

35. Bi Y, Guo X, Zhao H, Gao L, Wang L, Tang J, et al. Highly pathogenic porcine reproductive and respiratory syndrome virus induces prostaglandin E2 production through cyclooxygenase 1, which is dependent on the ERK1/2-p-C/EBP-β pathway. J Virol. 2014; 88(5):2810–2820. https://doi.org/10.1128/JVI.03205-13 PMID: 24352469

36. Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A. 2002; 99(6):3932–3937. https://doi.org/10.1073/pnas.052713799 PMID: 11867761
37. Chen N, Warer JL, Reiss CS. 2000. NSAID treatment suppresses VSV propagation in mouse CNS. Virology. 2000; 276(1):44–51. https://doi.org/10.1006/viro.2000.0562 PMID: 11021993

38. Pyeon D, Diaz FJ, Splitter GA. Prostaglandin E2 increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000; 74(12):5740–5745. PMID: 10823885

39. Tung WH, Hiiseh HL, Yang CH. Enterovirus 71 induces COX-2 expression via MAPKs, NF-kB, and AP-1 in SK-N-SH cells: role of PGE2 in viral replication. Cell Signal. 2010; 22(2):234–246. https://doi.org/10.1016/j.cellsig.2009.09.018 PMID: 19800403

40. Tung WH, Lee IT, Hiiseh HL, Yang CM. EV71 induces COX-2 expression via c-Src/PDGFR/Pi3K/Akt/p42/p44 MAPK/AP-1 and NF-kappaB in rat brain astrocytes. J Cell Physiol. 2010; 224(2):376–386. https://doi.org/10.1002/jcp.22133 PMID: 20333648

41. Lin CK, Tseng CK, Wu YH, Liaw CC, Lin CY, Huang CH, et al. Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents. Sci Rep. 2017; 7:44701. https://doi.org/10.1038/srep44701 PMID: 28317866

42. Lee SM, Gai WW, Cheung K, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res. 2011; 91(3):330–334. https://doi.org/10.1016/j.antiviral.2011.07.011 PMID: 21798291

43. Hyman A, Yim C, Krajden M, Read S, Basinski AS, Wanless I, et al. Oral prostaglandin (PGE2) treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation. 1994; 58(8):1897–1905. PMID: 8042236

44. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol. 2003; 41(10):1812–1819. PMID: 12767669

45. Dore-Duffy P. Differential effect of prostaglandins and other products of arachidonic acid metabolism on measles virus replication in Vero cells. Prostaglandins Leukotrienes Med. 2000; 74(12):5740–5745. PMID: 10823885

46. Chen CJ, Raung SL, Kuo MD, Wang YM. Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol. 2002; 83(Pt 8):1897–19055. https://doi.org/10.1099/0022-1317-83-8-1897 PMID: 12124453

47. Wang H, Zhang D, Ge M, Li Z, Jiang J, Li Y. 2015. Formononetin inhibits enterovirus 71 replication by regulating COX-2/PGE2 expression. Viriol J. 2015; 12:35. https://doi.org/10.1186/s12985-015-0264-x PMID: 25890183

48. Lin YT, Wu YH, Tseng CK, Lin CK, Chen WC, Hsu YC, et al. 2013. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cyclooxygenase-2 and attenuate virus-induced inflammation. PLoS One. 2013; 8(1):e54466. https://doi.org/10.1371/journal.pone.0054466 PMID: 23365670

49. Lin CK, Tseng CK, Chen KH, Wu SH, Liaw CC, Lee JC. 2015. Betulinic acid exerts anti-inflammatory effects on tick-borne encephalitis virus activity via the suppression of NF-kB and MAPK-ERK1/2-mediated COX-2 expression. Br J Pharmacol. 2015; 172:4481–4492. https://doi.org/10.1111/bph.13233 PMID: 26102077

50. Lee SM, Cheung CY, Nicholls JM, Hui KP, Leung CY, Uiprasertkul M, Tipoe GL, Lau YL, Poon LL, Ip NY, Guan Y, Peiris JS. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis. 2008; 198(4):525–535. https://doi.org/10.1086/590499 PMID: 18613795

51. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol. 2003; 41(10):1812–1819. PMID: 12767669

52. Khyatti M, Menezes J. The effect of indomethacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells. Antiviral Res. 1990; 14(3):161–172. PMID: 19643737

53. Janelle ME, Gravel A, Gosselin J, Tremblay MJ, Flamand L. Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 8. Role for cyclic AMP-responsive element-binding protein and activator protein-1. J Biol Chem. 2002; 277(34):30665–30674. https://doi.org/10.1074/jbc.M203041200 PMID: 12068008

54. Ray N, Bisher ME, Enquist LW. Cyclooxygenase-1 and 2 are required for production of infectious pseudorabies virus. J Virol. 2004; 78(3):12964–12974. https://doi.org/10.1128/JVI.78.23.12964-12974. 2004 PMID: 15542648

55. Flowers M, Sherker A, Sinclair SB, Greig PD, Cameron R, Phillips MJ, et al. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation. 1994; 58(2):183–192. PMID: 8042236

56. Luczak M, Gumulka W, Szmiugielski S, Korbecki M. Inhibition of multiplication of paramyxovirus 3 virus in prostaglandin-treated WISH cells. Arch Virol. 1975; 49(4):377–380. PMID: 174532
57. Moriuchi M, Inoue H, Moriuchi H. Reciprocal interactions between human T-lymphoropic virus type 1 and prostaglandins: implications for viral transmission. J Virol. 2001; 75(1):192–198. https://doi.org/10.1128/JVI.75.1.192-198.2001 PMID: 1119988

58. Kuno S, Ueno R, Hayashi O, Nakashima H, Harada S, Yamamoto N. Prostaglandin E2, a seminal constituent, facilitates the replication of acquired immune deficiency syndrome virus in vitro. Proc Natl Acad Sci U S A. 1986; 83(10):3487–3490. PMID: 3010301

59. Hayashi O, Harada S, Nakashima H. Substance affecting the infection and replication of human immunodeficiency virus (HIV). AIDS Res. 1986; 2(Suppl 1):S183–S189. PMID: 3030346

60. Hwang S, Alhatlani B, Arias A, Caddy SL, Constantina C, Cunha J, et al. Murine norovirus: propagation, quantification and genetic manipulation. Curr Protoc Microbiol. 2014; 33, 15K.2.1-15K.2.61. https://doi.org/10.1002/9780471729259.mc15k02s33 PMID: 24789596

61. Kim DS, Son KY, Koo KM, Kim JY, Alfajaro MM, Park JG, et al. Porcine sapelovirus uses α2,3-linked sialic acid on GD1α ganglioside as a receptor. J Virol. 2016; 90(8):4067–4077. https://doi.org/10.1128/JVI.02449-15 PMID: 26865725

62. Van Meerloo J, Kasper GJ, Cloos J. Cell sensitivity assays: MTT assay. Methods Mol Biol. 2011; 731: 237–245. https://doi.org/10.1007/978-1-61779-080-5_20 PMID: 21516412

63. Taube S, Perry JW, Yetming K, Patel SP, Auble H, Shu L, et al. Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J Virol. 2009; 83(9):4093–4101. https://doi.org/10.1128/JVI.02245-08 PMID: 19244326

64. Kim HJ, Park JG, Matthijnssens J, Lee JH, Bae YC, Alfajaro MM, et al. Vet Microbiol. 2011; 152(3–4): 291–303. https://doi.org/10.1016/j.vetmic.2011.05.017 PMID: 21658866

65. Park JG, Kim HJ, Matthijnssens J, Alfajaro MM, Kim DS, Son KY, et al. Different virulence of porcine and porcine-like bovine rotavirus strains with genetically nearly identical genomes in piglets and calves. Vet Res. 2013; 44:448. https://doi.org/10.1186/1297-9716-44-48 PMID: 24083947

66. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidem. 1938; 27(3): 493–497. https://doi.org/10.1093/oxfordjournals.aje.a118408

67. Kim DS, Hosmillo M, Alfajaro MM, Kim JY, Park JG, Son KY, et al. Both COX-2/PG E2 pathway enhances FCV and MNV replication and inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell Immunol. 2002; 215(1):61–71. PMID: 12142037

68. Yamamoto N, Harada S, Nakashima H. Substances affecting the infection and replication of human immunodeficiency virus (HIV). AIDS Res. 1986; 2(Suppl 1):S183–S189. PMID: 3030346

69. Warner TD, Mitchell JA. Cyclooxygenase: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004; 18(7):790–804. https://doi.org/10.1096/fj.03-0645rev PMID: 15117884

70. Zheng BJ, Chan KW, Zhao GY, Chan C, Zhang HJ, et al. Delayed antiviral plus immunomodulatory treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008; 105(23):8091–8096. https://doi.org/10.1073/pnas.0711942105 PMID: 18523003

71. Bi Z, Reiss CS. Inhibition of vesicular stomatitis virus infection by nitric oxide. J Virol. 1995; 69(4):2208–2213. PMID: 7533852

72. Heruff M, Svenungsson B, Lagergren A, Ljung T, Morcos E, Wiklund NP, et al. Increased nitric oxide in infective gastroenteritis. J Infect Dis. 1999; 180(2):542–545. https://doi.org/10.1086/314908 PMID: 10395879

73. Kash JC, Goodman AG, Korth MJ, Katze MG. Hijacking of the host-cell response and translational control during influenza virus infection. Virus Res. 2006 119(1):111–120. https://doi.org/10.1016/j.virusres.2005.10.013 PMID: 16630668

74. Somwanyarayan TN, Natarajan SK, Ramachandran A, Sarkar R, Moses PD, Simon A, et al. Nitric oxide production in acute gastroenteritis in Indian children. Trans R Soc Trop Med Hyg. 2009; 103 (8):849–851. https://doi.org/10.1016/j.trstmh.2009.05.003 PMID: 19552932

75. Zaki MH, Akuta T, Akaite T. Nitric oxide-induced nitrate stress involved in microbial pathogenesis. J Pharm Sci. 2005; 94(2):117–129. PMID: 15937405

76. Akaite T, Maeda H. Nitric oxide and virus infection. Immunology. 2000; 101(4):300–308.

77. Alvarez S, Serramia MJ, Fresno M, Muñoz-Fernández MA. HIV-1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in astrocytoma cells through a nuclear factor-kappaB-dependent mechanism. Neuromolecular Med. 2007; 9(2):170–193. PMID: 17627037
79. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A. 2001; 98(12):6905–6910. https://doi.org/10.1073/pnas.121016998 PMID: 11381123

80. Yan X, Hao Q, Mu Y, Timani KA, Ye L, Zhu Y, Wu J. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol. 2006; 38(8):1417–1428. https://doi.org/10.1016/j.biocel.2006.02.003 PMID: 16546436

81. Lu L, Zhang Q, Wu K, Chen X, Zheng Y, Zhu C, et al. 2015. Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-kB singal cascade. Cancer Lett. 2014; 356(2 Pt B):470478. https://doi.org/10.1016/j.canlet.2014.09.027 PMID: 25305454

82. Lu L, Wei L, Peng G, Mu Y, Wu K, Kang L, et al. NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. Virology. 2008; 371(1):61–70. https://doi.org/10.1016/j.virol.2007.09.025 PMID: 17964630